胰腺癌中miRNA的功能及临床研究进展

doi:10.3760/cma.j.issn.1007-1245.2023.13.004

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (13): 1790-1794.DOI: 10.3760/cma.j.issn.1007-1245.2023.13.004

胰腺癌中miRNA的功能及临床研究进展

朱鹏彭明珠吴莉莉

遂宁市第一人民医院消化内科，遂宁　629000

收稿日期:2023-02-17 出版日期:2023-07-01 发布日期:2023-07-21
通讯作者: 朱鹏，Email：tougaozhu001@163.com
基金资助:
四川省医学青年创新科研课题计划（Q19033）；四川省中医管理局中医药专项研究课题（2020JC0122）

Clinical research progress of miRNA in pancreatic cancer

Zhu Peng, Peng Mingzhu, Wu Lili

Department of Gastroenterology, The First People's Hospital of Suining, Suining 629000, China

Received:2023-02-17 Online:2023-07-01 Published:2023-07-21
Contact: Zhu Peng, Email: tougaozhu001@163.com
Supported by:
Sichuan Medical Youth Innovation Research Project (Q19033); Special Research Project of Traditional Chinese Medicine of Sichuan Provincial Administration of Traditional Chinese Medicine (2020JC0122)

摘要/Abstract

摘要：

胰腺癌是十分常见的消化系统恶性肿瘤，具有起病隐匿、恶性度高、临床预后差的特点。胰腺癌的致病机制十分复杂，多种因素在其中发挥调控作用。微RNA（miRNA）是不具有编码功能的短链RNA，其能够通过直接抑制靶基因的表达来发挥对人体生理病理功能的调控。大量的研究证据显示，胰腺癌中存在着大量特异性miRNA的异常表达，且这些miRNA在胰腺癌的致病及进展过程中发挥着重要的调节作用。同时，有临床研究显示，特异性miRNA作为无创生物学指标在用于胰腺癌的早期诊断及临床预后方面也具有重要的潜在价值。学者也尝试开发基于特定miRNA的胰腺癌治疗方法，虽然仅停留在基础研究结果，但是仍为寻找新的胰腺癌治疗方法提供了重要参考。

关键词:

胰腺癌, 微RNA, 诊断, 治疗, 预后, 进展

Abstract:

Pancreatic cancer (PC) is a very common malignant tumor of the digestive system, with obscure onset, high malignancy, and poor prognosis. The pathogenesis of PC is very complex, and many factors play a regulatory role. miRNA is a short strand RNA which does not have coding function, and it can regulate the physiological and pathological functions by directly inhibiting the expression of target genes. A large number of studies have shown that specific miRNAs are abnormally expressed in PC, and these miRNAs play important regulatory roles in the pathogenesis and progression of PC. At the same time, clinical studies have shown that specific miRNAs, as non-invasive biological indicators, also have important potential values in the early diagnosis and clinical prognosis of PC. Scholars have also tried to develop PC therapeutics based on specific miRNAs. Although the results are only basic at present, they still provide an important reference for searching for new PC therapeutics.

Key words:

Pancreatic cancer, miRNA, Diagnosis, Treatment, Prognosis, Progress

朱鹏彭明珠吴莉莉.

胰腺癌中miRNA的功能及临床研究进展 [J]. 国际医药卫生导报, 2023, 29(13): 1790-1794.

Zhu Peng, Peng Mingzhu, Wu Lili.

Clinical research progress of miRNA in pancreatic cancer [J]. International Medicine and Health Guidance News, 2023, 29(13): 1790-1794.

参考文献

[1] Bakasa W, Viriri S. Pancreatic cancer survival prediction: a survey of the state-of-the-art[J]. Comput Math Methods Med, 2021, 2021: 1188414. DOI: 10.1155/2021/1188414.
[2] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[3] Dai H, Abdullah R, Wu X, et al. Pancreatic cancer: nucleic acid drug discovery and targeted therapy[J]. Front Cell Dev Biol, 2022, 10: 855474. DOI: 10.3389/fcell.2022.855474.
[4] Dexheimer PJ, Cochella L. MicroRNAs: from mechanism to organism[J]. Front Cell Dev Biol, 2020, 8: 409. DOI: 10.3389/fcell.2020.00409.
[5] Smolarz B, Durczyński A, Romanowicz H, et al. The role of microRNA in pancreatic cancer[J]. Biomedicines, 2021, 9(10): 1322. DOI: 10.3390/biomedicines9101322.
[6] Cheong JK, Tang YC, Zhou L, et al. Advances in quantifying circulatory microRNA for early disease detection[J]. Curr Opin Biotechnol, 2022, 74: 256-262. DOI: 10.1016/j.copbio.2021.12.007.
[7] Li X, Jiang W, Gan Y, et al. The application of exosomal MicroRNAs in the treatment of pancreatic cancer and its research progress[J]. Pancreas, 2021, 50(1): 12-16. DOI: 10.1097/MPA.0000000000001713.
[8] Wang P, Zheng D, Qi H, et al. miR-125b enhances metastasis and progression of cancer via the TXNIP and HIF1alpha pathway in pancreatic cancer[J]. Cancer Biomark, 2021, 31(1): 27-38. DOI: 10.3233/CBM-203112.
[9] Wang S, Gao Y. Pancreatic cancer cell-derived microRNA-155-5p-containing extracellular vesicles promote immune evasion by triggering EHF-dependent activation of Akt/NF-kappaB signaling pathway[J]. Int Immunopharmacol, 2021, 100: 107990. DOI: 10.1016/j.intimp.2021.107990.
[10] Tian T, Yang Q, Zhang C, et al. MiRNA-107 enhances the malignant progression of pancreatic cancer by targeting TGFBR3[J]. PLoS One, 2021, 16(5): e0249375. DOI: 10.1371/journal.pone.0249375.
[11] Niu G, Hao J, Sheng S, et al. Role of T-box genes in cancer, epithelial-mesenchymal transition, and cancer stem cells[J]. J Cell Biochem, 2022, 123(2): 215-230. DOI: 10.1002/jcb.30188.
[12] Gu Y, Yuan J. Diagnostic significance of miRNAs as potential biomarkers for human renal cell carcinoma: a systematic review and meta-analysis[J]. Expert Rev Anticancer Ther, 2022, 22(4): 437-444. DOI: 10.1080/14737140.2022.2051483.
[13] Kang H, Ma D, Zhang J, et al. MicroRNA-18a induces epithelial-mesenchymal transition like cancer stem cell phenotype via regulating RKIP pathway in pancreatic cancer[J]. Ann Transl Med, 2020, 8(7): 433. DOI: 10.21037/atm.2020.03.195
[14] Xue Y, Wu T, Sheng Y, et al. MicroRNA-1252-5p, regulated by Myb, inhibits invasion and epithelial-mesenchymal transition of pancreatic cancer cells by targeting NEDD9[J]. Aging (Albany NY), 2021, 13(14): 18924-18945. DOI: 10.18632/aging.203344.
[15] 傅冰洁, 俞霞, 李付贵, 等. CA199联合血清异常凝血酶原在胰腺癌早期诊断中的临床价值[J]. 国际医药卫生导报,2020, 26(7): 973-976. DOI: 10.3760/cma.j.issn.1007-1245.2020.07.025.
[16] Sempere LF, Powell K, Rana J, et al. Role of non-coding RNAs in tumor progression and metastasis in pancreatic cancer[J]. Cancer Metastasis Rev, 2021, 40(3): 761-776. DOI: 10.1007/s10555-021-09995-x.
[17] Eid M, Karousi P, Kunovsky L, et al. The role of circulating MicroRNAs in patients with early-stage pancreatic adenocarcinoma[J]. Biomedicines, 2021, 9(10): 1468. DOI: 10.3390/biomedicines9101468.
[18] Ishige F, Hoshino I, Iwatate Y, et al. MIR1246 in body fluids as a biomarker for pancreatic cancer[J]. Sci Rep, 2020, 10(1): 8723. DOI: 10.1038/s41598-020-65695-6.
[19] Peng C, Wang J, Gao W, et al. Meta-analysis of the diagnostic performance of circulating microRNAs for pancreatic cancer[J]. Int J Med Sci, 2021, 18(3): 660-671. DOI: 10.7150/ijms.52706.
[20] Guo S, Qin H, Liu K, et al. Blood small extracellular vesicles derived miRNAs to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis[J]. Clin Transl Med, 2021, 11(9): e520. DOI: 10.1002/ctm2.520.
[21] Lee J, Lee HS, Park SB, et al. Identification of circulating serum miRNAs as novel biomarkers in pancreatic cancer using a penalized algorithm[J]. Int J Mol Sci, 2021, 22(3) :1007. DOI: 10.3390/ijms22031007.
[22] Zhao F, Wei C, Cui MY, et al. Prognostic value of microRNAs in pancreatic cancer: a meta-analysis[J]. Aging (Albany NY), 2020, 12(10): 9380-9404. DOI: 10.18632/aging.103214.
[23] Li Y, Wang Z, Zhao F, et al. MicroRNA190b expression predicts a good prognosis and attenuates the malignant progression of pancreatic cancer by targeting MEF2C and TCF4[J]. Oncol Rep, 2022, 47(1): 12. DOI: 10.3892/or.2021.8223.
[24] Sebastian NT, Webb A, Merrell KW, et al. Development of a MicroRNA signature predictive of recurrence and survival in pancreatic ductal adenocarcinoma[J]. Cancers (Basel), 2021, 13(20): 5168. DOI: 10.3390/cancers13205168.
[25] van der Sijde F, Homs MYV, van Bekkum ML, et al. Serum miR-373-3p and miR-194-5p are associated with early tumor progression during FOLFIRINOX treatment in pancreatic cancer patients: a prospective multicenter study[J]. Int J Mol Sci, 2021, 22(20): 10902. DOI: 10.3390/ijms222010902.
[26] Chu X, Wei D, Liu X, et al. MicroRNAs as potential therapeutic targets for pancreatic cancer[J]. Chin Med J (Engl), 2021, 135(1): 4-10. DOI: 10.1097/CM9.0000000000001826.
[27] Fu XF, Zhao HC, Yang CL, et al. MicroRNA-203-3p inhibits the proliferation, invasion and migration of pancreatic cancer cells by downregulating fibroblast growth factor 2[J]. Oncol Lett, 2021, 22(2): 626. DOI: 10.3892/ol.2021.12887.
[28] Lei S, Zeng Z, He Z, et al. miRNA7515 suppresses pancreatic cancer cell proliferation, migration and invasion via downregulating IGF1 expression[J]. Oncol Rep, 2021, 46(3): 200. DOI: 10.3892/or.2021.8151.
[29] Liu W, Li X, Tan X, et al. MicroRNA-204-3p inhibits metastasis of pancreatic cancer via downregulating MGAT1[J]. J BUON, 2021, 26(5): 2149-2156.
[30] Zhang D, He Z, Shen Y, et al. MiR-489-3p reduced pancreatic cancer proliferation and metastasis by targeting PKM2 and LDHA involving glycolysis[J]. Front Oncol, 2021, 11: 651535. DOI: 10.3389/fonc.2021. 651535.
[31] Wang J, Xie Z, Liu Y, et al. MicroRNA-361 reduces the viability and migratory ability of pancreatic cancer cells via mediation of the MAPK/JNK pathway[J]. Exp Ther Med, 2021, 22(6): 1365. DOI: 10.3892/etm.2021.10799
[32] Pan Y, Li K, Tao X, et al. MicroRNA-34a alleviates gemcitabine resistance in pancreatic cancer by repression of cancer stem cell renewal[J]. Pancreas, 2021, 50(9): 1260-1266. DOI: 10.1097/MPA.0000000000001920.
[33] Shopit A, Li X, Wang S, et al. Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabine resistant pancreatic cancer cells[J]. Phytomedicine, 2021, 91: 153711. DOI: 10.1016/j.phymed.2021.153711.

胰腺癌中miRNA的功能及临床研究进展

Clinical research progress of miRNA in pancreatic cancer

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	温诗瑜温炬冯颖君李慕锦秦思. 生物制剂在银屑病中的临床应用 [J]. 国际医药卫生导报, 2023, 29(9): 1185-1188.
[2]	詹泽宇林思恩魏波. 骨肉瘤临床治疗现状与创新疗法研究进展 [J]. 国际医药卫生导报, 2023, 29(9): 1197-1200..
[3]	侯长冉姜京汝花义同. 软骨素聚合因子在乳腺癌中的研究进展 [J]. 国际医药卫生导报, 2023, 29(9): 1201-1204.
[4]	宁向红孙建张德刚张志伟李孟奇杨智杨淑野张锴李朋. 超声诊断Morel-Lavallée损伤的临床应用价值 [J]. 国际医药卫生导报, 2023, 29(9): 1239-1244.
[5]	柯金王恒石张善兰. 卡瑞利珠单抗免疫相关不良反应临床分析 [J]. 国际医药卫生导报, 2023, 29(9): 1258-1262.
[6]	丁愫莹李玲玲丁炀. SWI联合DWI在脑出血急性期中的诊断价值 [J]. 国际医药卫生导报, 2023, 29(9): 1272-1275.
[7]	王泽川黄月琴. 急性髓系白血病靶向药物治疗新进展 [J]. 国际医药卫生导报, 2023, 29(8): 1045-1048.
[8]	徐仕杰罗泽斌陈晓东. CT肺动脉成像在肺栓塞诊治中的应用进展 [J]. 国际医药卫生导报, 2023, 29(8): 1053-1056.
[9]	海花陈金金鲁苏日古嘎. 食管测压联合食管24 h pH监测对胃食管反流相关性胸痛的诊断价值 [J]. 国际医药卫生导报, 2023, 29(8): 1071-1074.
[10]	肖晶晶姚蕾张萍. 智谋理论支持下的多维度心理干预在结核病咯血患者中的应用效果 [J]. 国际医药卫生导报, 2023, 29(8): 1155-1159.
[11]	宋玉丽张书巧南园园. 全身型幼年特发性关节炎并发巨噬细胞活化综合征的护理诊断及干预要点 [J]. 国际医药卫生导报, 2023, 29(8): 1171-1175.
[12]	张衡潘广涛殷鸣张平尹霞. 自体脂肪移植在整形外科中的研究进展 [J]. 国际医药卫生导报, 2023, 29(7): 889-892.
[13]	张琪赵燕超. 奥美拉唑注射液联合肠内营养支持治疗急性胰腺炎患者的效果 [J]. 国际医药卫生导报, 2023, 29(7): 978-982.
[14]	梅嘉洺杨育生. 直肠黏膜施万细胞错构瘤3例临床病理分析 [J]. 国际医药卫生导报, 2023, 29(7): 995-998.
[15]	袁法伟李炳奇. 体外膜肺氧合治疗呼吸衰竭的效果及预后分析 [J]. 国际医药卫生导报, 2023, 29(7): 973-977.